• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by BiomX Inc.

    10/25/24 9:25:22 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-38762
    Issuer: BiomX Inc.
    Exchange: NYSE AMERICAN LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 17 State Street 21st Floor
    New York NEW YORK 10004
    Telephone number:  
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, NYSE AMERICAN LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-10-25 By Nicolas Connolly Analyst, Regulation
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    2/10/26 4:29:14 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by BiomX Inc.

    S-3 - BiomX Inc. (0001739174) (Filer)

    2/9/26 4:33:55 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by BiomX Inc.

    PRE 14A - BiomX Inc. (0001739174) (Filer)

    2/3/26 5:19:03 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Issues Statement Regarding Recent Common Stock Trading Activity

    NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock. NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement

    1/27/26 1:41:26 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

    Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) --  BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced its discontinuation of the ongoing Phase

    12/8/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yeganeh Reuven

    3 - BiomX Inc. (0001739174) (Issuer)

    1/16/26 7:59:12 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by *Director by Deputization Flynn James E

    4 - BiomX Inc. (0001739174) (Issuer)

    4/23/25 5:49:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by Director Merril Gregory Louis

    4/A - BiomX Inc. (0001739174) (Issuer)

    4/21/25 8:24:29 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Announces the Appointment of Susan Blum to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

    4/18/24 8:00:00 AM ET
    $PHGE
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Telum Therapeutics appoints Dr. Subhendu Basu as CEO

    Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

    3/19/24 5:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

    10/18/23 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

    Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

    11/12/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

    NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to discuss the third quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the sta

    11/5/25 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care